SCHEMBL1102120

SCHEMBL1102120

O=C(CCn1ccc2cccc(Cl)c21)Nc1ccc(S(=O)(=O)Nc2ncns2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 11/20 0.47
SCN5A Q14524 6/20 0.47
LMNA P02545 2/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 2/20 0.41
SCN1A P35498 1/20 0.41
SCN8A Q9UQD0 1/20 0.41
PKM P14618 1/20 0.41
HCRTR1 O43613 1/20 0.41
USP2 O75604 1/20 0.41
PPARG P37231 1/20 0.41
HTT P42858 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102119 0.91 SCN9A (0.48) SCN9ASCN5ALMNAMAPTPOLB
SCHEMBL1102021 0.90 PKM (0.42) SCN9ASCN5ALMNATSHRSMN1; SMN2
SCHEMBL9972277 0.86 LMNA (0.59) SCN9ASCN5ALMNATSHRSMN1; SMN2
SCHEMBL1102059 0.85 LMNA (0.41) SCN9ASCN5ALMNATSHRSMN1; SMN2
SCHEMBL10310818 0.83 SCN8A (0.42) SCN9ASCN5ASCN1ASCN8A
SCHEMBL1102133 0.83 KMO (0.45) SCN9ASCN5A
SCHEMBL1102109 0.83 SCN9A (0.45) SCN9ASCN5A
SCHEMBL10200628 0.82 MAPT (0.42) SCN9ASCN5ASMN1; SMN2MAPTPOLB
SCHEMBL13403975 0.81 MEN1 (0.44) SCN9ALMNATSHRSMN1; SMN2MAPT
SCHEMBL2626079 0.81 SCN9A (0.42) SCN9ASCN5ASCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 US disclosed
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 SCN9A 70/4885SCN5A 11/4885LMNA 1374/4885
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels SCNN1G, KCNN3, KCNN2 SCN9A 70/4885SCN5A 11/4885LMNA 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.